Market Closed -
Japan Exchange
02:00:00 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
2,773
JPY
|
-0.11%
|
|
+0.84%
|
+17.90%
|
03-25 |
Towa Pharmaceutical Completes Payment for Director Stock Compensation
|
MT
| 03-07 |
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors
|
CI
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
143,346
|
111,557
|
120,231
|
135,736
|
93,275
|
136,485
|
-
|
-
|
Enterprise Value (EV)
1 |
178,664
|
175,237
|
179,706
|
247,034
|
242,083
|
299,016
|
298,179
|
293,450
|
P/E ratio
|
10.6
x
|
7.69
x
|
8.61
x
|
8.5
x
|
42.4
x
|
10.7
x
|
11.7
x
|
10.6
x
|
Yield
|
1.23%
|
1.94%
|
1.8%
|
2.18%
|
3.17%
|
2.16%
|
2.18%
|
2.2%
|
Capitalization / Revenue
|
1.36
x
|
1.01
x
|
0.78
x
|
0.82
x
|
0.45
x
|
0.59
x
|
0.56
x
|
0.52
x
|
EV / Revenue
|
1.7
x
|
1.59
x
|
1.16
x
|
1.49
x
|
1.16
x
|
1.3
x
|
1.21
x
|
1.12
x
|
EV / EBITDA
|
7.35
x
|
7.17
x
|
6.07
x
|
8.19
x
|
9.71
x
|
8.8
x
|
8.17
x
|
7.67
x
|
EV / FCF
|
22.1
x
|
-8.6
x
|
61.8
x
|
-6.57
x
|
-8.73
x
|
-17.9
x
|
-70.9
x
|
30.3
x
|
FCF Yield
|
4.53%
|
-11.6%
|
1.62%
|
-15.2%
|
-11.5%
|
-5.59%
|
-1.41%
|
3.3%
|
Price to Book
|
1.56
x
|
1.07
x
|
1.03
x
|
1.02
x
|
0.68
x
|
0.93
x
|
0.87
x
|
0.82
x
|
Nbr of stocks (in thousands)
|
49,209
|
49,209
|
49,215
|
49,394
|
49,222
|
49,219
|
-
|
-
|
Reference price
2 |
2,913
|
2,267
|
2,443
|
2,748
|
1,895
|
2,773
|
2,773
|
2,773
|
Announcement Date
|
19-05-14
|
20-05-14
|
21-05-14
|
22-05-13
|
23-05-15
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
105,104
|
110,384
|
154,900
|
165,615
|
208,859
|
229,894
|
245,836
|
261,816
|
EBITDA
1 |
24,308
|
24,428
|
29,597
|
30,159
|
24,923
|
33,967
|
36,500
|
38,250
|
EBIT
1 |
15,968
|
16,143
|
19,923
|
19,205
|
5,514
|
15,794
|
17,888
|
19,850
|
Operating Margin
|
15.19%
|
14.62%
|
12.86%
|
11.6%
|
2.64%
|
6.87%
|
7.28%
|
7.58%
|
Earnings before Tax (EBT)
1 |
18,886
|
20,709
|
18,728
|
22,246
|
4,605
|
19,662
|
18,235
|
20,295
|
Net income
1 |
13,475
|
14,503
|
13,958
|
15,914
|
2,201
|
12,715
|
11,658
|
12,903
|
Net margin
|
12.82%
|
13.14%
|
9.01%
|
9.61%
|
1.05%
|
5.53%
|
4.74%
|
4.93%
|
EPS
2 |
273.8
|
294.7
|
283.6
|
323.4
|
44.72
|
258.3
|
236.8
|
262.1
|
Free Cash Flow
1 |
8,087
|
-20,377
|
2,908
|
-37,600
|
-27,740
|
-16,716
|
-4,205
|
9,671
|
FCF margin
|
7.69%
|
-18.46%
|
1.88%
|
-22.7%
|
-13.28%
|
-7.27%
|
-1.71%
|
3.69%
|
FCF Conversion (EBITDA)
|
33.27%
|
-
|
9.83%
|
-
|
-
|
-
|
-
|
25.28%
|
FCF Conversion (Net income)
|
60.01%
|
-
|
20.83%
|
-
|
-
|
-
|
-
|
74.95%
|
Dividend per Share
2 |
35.83
|
44.00
|
44.00
|
60.00
|
60.00
|
60.00
|
60.40
|
61.00
|
Announcement Date
|
19-05-14
|
20-05-14
|
21-05-14
|
22-05-13
|
23-05-15
|
-
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
55,350
|
74,640
|
39,327
|
82,254
|
43,359
|
40,002
|
45,372
|
45,128
|
90,500
|
49,905
|
68,454
|
54,548
|
52,848
|
107,396
|
60,929
|
61,606
|
56,900
|
55,700
|
63,200
|
65,200
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
2,894
|
-
|
-
|
-
|
-
|
EBIT
1 |
9,218
|
8,782
|
4,231
|
10,312
|
6,681
|
2,212
|
1,940
|
1,280
|
3,220
|
2,132
|
162
|
4,096
|
2,907
|
7,003
|
6,201
|
2,496
|
3,998
|
3,348
|
6,084
|
3,470
|
Operating Margin
|
16.65%
|
11.77%
|
10.76%
|
12.54%
|
15.41%
|
5.53%
|
4.28%
|
2.84%
|
3.56%
|
4.27%
|
0.24%
|
7.51%
|
5.5%
|
6.52%
|
10.18%
|
4.05%
|
7.03%
|
6.01%
|
9.63%
|
5.32%
|
Earnings before Tax (EBT)
1 |
9,738
|
8,655
|
5,329
|
13,043
|
8,080
|
-
|
2,572
|
2,008
|
4,580
|
-413
|
-
|
7,140
|
3,252
|
10,392
|
6,898
|
2,609
|
3,898
|
3,248
|
5,984
|
3,770
|
Net income
1 |
7,066
|
6,251
|
3,931
|
9,242
|
5,758
|
914
|
1,395
|
1,297
|
2,692
|
-708
|
217
|
4,750
|
2,203
|
6,953
|
4,565
|
1,046
|
2,698
|
2,248
|
4,184
|
2,670
|
Net margin
|
12.77%
|
8.37%
|
10%
|
11.24%
|
13.28%
|
2.28%
|
3.07%
|
2.87%
|
2.97%
|
-1.42%
|
0.32%
|
8.71%
|
4.17%
|
6.47%
|
7.49%
|
1.7%
|
4.74%
|
4.04%
|
6.62%
|
4.1%
|
EPS
2 |
143.6
|
127.0
|
79.87
|
187.8
|
117.0
|
-
|
28.34
|
26.36
|
54.70
|
-14.38
|
-
|
96.51
|
44.75
|
141.3
|
92.77
|
-14.71
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
22.00
|
22.00
|
-
|
27.00
|
-
|
-
|
-
|
-
|
30.00
|
-
|
-
|
-
|
30.00
|
30.00
|
-
|
30.00
|
-
|
30.00
|
-
|
30.00
|
Announcement Date
|
19-11-11
|
20-11-13
|
21-11-12
|
21-11-12
|
22-02-14
|
22-05-13
|
22-08-10
|
22-11-14
|
22-11-14
|
23-02-13
|
23-05-15
|
23-08-10
|
23-11-13
|
23-11-13
|
24-02-13
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
35,318
|
63,680
|
59,475
|
111,298
|
148,808
|
162,531
|
161,694
|
156,966
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.453
x
|
2.607
x
|
2.009
x
|
3.69
x
|
5.971
x
|
4.785
x
|
4.43
x
|
4.104
x
|
Free Cash Flow
1 |
8,087
|
-20,377
|
2,908
|
-37,600
|
-27,740
|
-16,716
|
-4,205
|
9,671
|
ROE (net income / shareholders' equity)
|
15.7%
|
14.8%
|
12.6%
|
12.8%
|
1.6%
|
8.94%
|
7.67%
|
7.99%
|
ROA (Net income/ Total Assets)
|
10.3%
|
10.1%
|
7.88%
|
7.9%
|
1.47%
|
4.1%
|
3.8%
|
4.35%
|
Assets
1 |
130,760
|
144,042
|
177,046
|
201,419
|
150,119
|
310,113
|
306,784
|
296,623
|
Book Value Per Share
2 |
1,865
|
2,126
|
2,369
|
2,685
|
2,781
|
2,997
|
3,180
|
3,389
|
Cash Flow per Share
|
443.0
|
463.0
|
480.0
|
530.0
|
334.0
|
-
|
-
|
-
|
Capex
1 |
11,143
|
4,549
|
9,137
|
14,848
|
39,645
|
38,500
|
20,925
|
16,825
|
Capex / Sales
|
10.6%
|
4.12%
|
5.9%
|
8.97%
|
18.98%
|
16.75%
|
8.51%
|
6.43%
|
Announcement Date
|
19-05-14
|
20-05-14
|
21-05-14
|
22-05-13
|
23-05-15
|
-
|
-
|
-
|
Last Close Price
2,773
JPY Average target price
3,690
JPY Spread / Average Target +33.07% Consensus |
1st Jan change
|
Capi.
|
---|
| +17.90% | 867M | | +25.73% | 661B | | +26.74% | 566B | | -6.71% | 352B | | +18.85% | 332B | | +3.33% | 283B | | +13.43% | 231B | | +4.71% | 200B | | -9.53% | 195B | | -4.36% | 145B |
Other Pharmaceuticals
|